NEW YORK, January 13, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals International, Inc. (NYSE: VRX), XOMA Corporation (NASDAQ: XOMA), Gentium S.p.A (NASDAQ: GENT), Magellan Health Services Inc. (NASDAQ: MGLN), and Abiomed Inc. (NASDAQ: ABMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Valeant Pharmaceuticals International, Inc. Research Report
Valeant Pharmaceuticals International, Inc. (Valeant) posted on the events page of the Company's website that it will participate at the 32nd Annual J.P. Morgan Healthcare Conference, which will be held from January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco, California. According to the Company, Valeant's scheduled presentation at the aforesaid conference will be webcast live on January 14th, 2014, at 3:30 p.m. PST via Valeant's website. The Full Research Report on Valeant Pharmaceuticals International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/9fdd_VRX
--
XOMA Corporation Research Report
On January 8, 2014, XOMA Corporation's (XOMA) stock increased 2.29%, ending the day's trading session at $7.16. Over the previous three trading sessions, shares of XOMA increased 0.99%, compared to the Nasdaq Composite Index, which increased 0.82% during the same period. The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/9a56_XOMA
--
Gentium S.p.A Research Report
On January 8, 2014, Gentium S.p.A's (Gentium) stock declined 0.16%, ending the day's trading session at $57.00. Over the previous three trading sessions, shares of Gentium remained flat, compared to the Nasdaq Composite Index which increased 0.82% during the same period. The Full Research Report on Gentium S.p.A - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/e100_GENT
--
Magellan Health Services Inc. Research Report
Magellan Health Services Inc. (Magellan) posted on the events page of the Company's website that it will take part in the 32nd Annual J.P. Morgan Healthcare Conference on January 14, 2014 at 2:00 p.m. PT. The Full Research Report on Magellan Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/4b85_MGLN
--
Abiomed Inc. Research Report
On January 8, 2014, Abiomed Inc.'s (Abiomed) stock increased 2.21%, ending the day's trading session at $28.23. Over the previous three trading sessions, shares of Abiomed increased 4.32%, compared to the Nasdaq Composite Index which increased 0.82% during the same period. The Full Research Report on Abiomed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/ea34_ABMD
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
